Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy L Rose

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2022
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO GuidelineW Kimryn Rathmell, R Bryan Rumble, Peter J Van Veldhuizen, et al.
Nature Communications|December 13, 2025
APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signalingMichael S Sturdivant, Andrew S Truong, Mi Zhou, et al.
British Journal of Cancer|March 12, 2022
Correction to: Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experienceTracy L Rose, William H Weir, Gregory M Mayhew, et al.
British Journal of Cancer|July 23, 2021
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experienceTracy L Rose, William H Weir, Gregory M Mayhew, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2021
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder CancerTracy L Rose, Michael R Harrison, Allison M Deal, et al.
Bladder Cancer (Amsterdam, Netherlands)|December 31, 2016
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder CancerTracy L Rose, Allison M Deal, Sylvain Ladoire, et al.
Nature Communications|May 24, 2024
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancerWolfgang Beckabir, Mi Zhou, Jin Seok Lee, et al.
The Journal of Clinical Investigation|January 16, 2024
FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppressionAtsushi Okato, Takanobu Utsumi, Michela Ranieri, et al.
Eclinicalmedicine|June 12, 2023
Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective studyCassandra Duarte, Junxiao Hu, Benoit Beuselinck, et al.
Clinical Genitourinary Cancer|March 10, 2020
Pilot Study of [<sup>18</sup>F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC)Patrick J Eulitt, Ersan Altun, Arif Sheikh, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2022
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO GuidelineW Kimryn Rathmell, R Bryan Rumble, Peter J Van Veldhuizen, et al.
Nature Communications|December 13, 2025
APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signalingMichael S Sturdivant, Andrew S Truong, Mi Zhou, et al.
British Journal of Cancer|March 12, 2022
Correction to: Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experienceTracy L Rose, William H Weir, Gregory M Mayhew, et al.
British Journal of Cancer|July 23, 2021
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experienceTracy L Rose, William H Weir, Gregory M Mayhew, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2021
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder CancerTracy L Rose, Michael R Harrison, Allison M Deal, et al.
Bladder Cancer (Amsterdam, Netherlands)|December 31, 2016
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder CancerTracy L Rose, Allison M Deal, Sylvain Ladoire, et al.
Nature Communications|May 24, 2024
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancerWolfgang Beckabir, Mi Zhou, Jin Seok Lee, et al.
The Journal of Clinical Investigation|January 16, 2024
FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppressionAtsushi Okato, Takanobu Utsumi, Michela Ranieri, et al.
Eclinicalmedicine|June 12, 2023
Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective studyCassandra Duarte, Junxiao Hu, Benoit Beuselinck, et al.
Clinical Genitourinary Cancer|March 10, 2020
Pilot Study of [<sup>18</sup>F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC)Patrick J Eulitt, Ersan Altun, Arif Sheikh, et al.
Pageof 7